Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell CarcinomaGlobeNewsWire • 05/02/23
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®GlobeNewsWire • 05/01/23
Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual MeetingGlobeNewsWire • 04/26/23
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant SettingGlobeNewsWire • 04/17/23
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023GlobeNewsWire • 03/31/23
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung CancerGlobeNewsWire • 03/30/23
Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO's European Lung Cancer Congress 2023GlobeNewsWire • 03/23/23
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast CancerGlobeNewsWire • 03/14/23
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck CancerGlobeNewsWire • 01/04/23
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast CancerGlobeNewsWire • 12/23/22
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod AlphaGlobeNewsWire • 12/08/22
Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune DiseaseGlobeNewsWire • 12/06/22
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial CancerGlobeNewsWire • 11/29/22
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual MeetingGlobeNewsWire • 11/10/22
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022GlobeNewsWire • 11/10/22
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy CombinationGlobeNewsWire • 11/09/22
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press ConferenceGlobeNewsWire • 11/04/22